Clinical trials: sponsored by Genmab
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Diffuse Large B-Cell Lymphoma
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
The purpose of this Chinese sub-study trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in…
- Trial name
- NCT07226752
- Testing
- Epcoritamab, Investigator's Choice Chemotherapy
- Where
- 23 sites in China
- Volunteers
- 72 people
- Sponsor
- Genmab
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Renal Cell Carcinoma, Nasopharyngeal Carcinoma
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
- Conditions
- Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
- Trial name
- NCT05721222
- Testing
- GEN1160
- Where
- 17 sites in United States, China
- Volunteers
- 42 people
- Sponsor
- Genmab
Malignant Solid Tumor
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
The purpose of this trial is to measure the following in participants with solid cancers who receive GEN1078. The side effects seen with GEN1078 What the body does with GEN1078 once it is administered What GEN1078 does to the…
- Trial name
- NCT06771921
- Testing
- GEN1078
- Where
- 6 sites in Denmark, Spain
- Volunteers
- 3 people
- Sponsor
- Genmab
Solid Tumor, Adult
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor…
- Trial name
- NCT05586321
- Testing
- GEN1056
- Where
- 7 sites in Georgia, Moldova and 1 more
- Volunteers
- 26 people
- Sponsor
- Genmab
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory…
- Trial name
- NCT06018129
- Testing
- GEN3017
- Where
- 4 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Genmab
Solid Tumor
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with…
- Trial name
- NCT04937153
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Genmab
Solid Tumor, Adult
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity.
- Trial name
- NCT05435339
- Testing
- GEN1053
- Where
- 5 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- Genmab
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety.
- Conditions
- Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT04358458
- Testing
- GEN3009, Epcoritamab
- Where
- 17 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genmab
Advanced Endometrial Cancer
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer…
- Trial name
- NCT06046274
- Testing
- Pembrolizumab, Acasunlimab
- Where
- 29 sites in United States, Belgium and 4 more
- Sponsor
- Genmab
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Non-curable Patients With SCCHN
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
- Trial name
- NCT00542308
- Testing
- Zalutumumab
- Where
- 48 sites in United States, Austria and 9 more
- Volunteers
- 90 people
- Sponsor
- Genmab
Head and Neck Cancer, Squamous Cell Carcinoma
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.
- Trial name
- NCT00707655
- Testing
- Zalutumumab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Genmab
Head and Neck Cancer
Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is to support current and future Zalutumumab studies by increasing the Pharmacokinetic (PK) knowledge of the drug. PK is the study of how a drug is absorbed (taken up), distributed (moved around), metabolised (broken…
- Trial name
- NCT01054625
- Testing
- zalutumumab
- Where
- 7 sites in Belgium, Hungary and 2 more
- Volunteers
- 31 people
- Sponsor
- Genmab
Ovarian Cancer, Cervical Cancer
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02988817
- Testing
- Enapotamab vedotin (HuMax-AXL-ADC)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 306 people
- Sponsor
- Genmab
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Colorectal Cancer
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
- Trial name
- GEN206 (NCT00677924)
- Testing
- Zalutumumab
- Where
- 3 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Genmab
Head and Neck Neoplasms
Zalutumumab in Head and Neck Cancer
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
- Trial name
- NCT00093041
- Testing
- Zalutumumab
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Genmab
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Expanded Access Program for Epcoritamab
The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT05733650
- Testing
- Epcoritamab
- Sponsor
- Genmab